{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:21:31Z","timestamp":1770067291397,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00108-022-01297-w","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T07:02:29Z","timestamp":1649142149000},"page":"1200-1207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neue Aspekte der medikament\u00f6sen Nephroprotektion","New aspects of pharmacological nephroprotection"],"prefix":"10.1007","volume":"63","author":[{"given":"J\u00f6rg","family":"Beimler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"issue":"1","key":"1297_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"A Levin","year":"2013","unstructured":"Levin\u00a0A, Stevens\u00a0PE, Bilous\u00a0RW, Coresh\u00a0J, De Francisco\u00a0ALM, De Jong\u00a0PE, Griffith\u00a0KE, Hemmelgarn\u00a0BR, Iseki\u00a0K, Lamb\u00a0EJ, Levey\u00a0AS, Riella\u00a0MC, Shlipak\u00a0MG, Wang\u00a0H, White\u00a0CT, Winearls\u00a0CG (2013) Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1\u2013150","journal-title":"Kidney Int Suppl"},{"issue":"10302","key":"1297_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh\u00a0K, Jafar\u00a0TH, Nitsch\u00a0D, Neuen\u00a0BL, Perkovic\u00a0V (2021) Chronic kidney disease. Lancet 398(10302):786\u2013802","journal-title":"Lancet"},{"issue":"1","key":"1297_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","volume":"73","author":"R Malhotra","year":"2019","unstructured":"Malhotra\u00a0R, Craven\u00a0T, Ambrosius\u00a0WT, Killeen\u00a0AA, Haley\u00a0WE, Cheung\u00a0AK, Chonchol\u00a0M, Sarnak\u00a0M, Parikh\u00a0CR, Shlipak\u00a0MG, Ix\u00a0JH, SPRINT Research Group (2019) Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT. Am J Kidney Dis 73(1):21\u201330","journal-title":"Am J Kidney Dis"},{"issue":"3S","key":"1297_CR4","first-page":"S1","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3S):S1\u2013S87","journal-title":"Kidney Int"},{"issue":"1","key":"1297_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1470320312439140","volume":"13","author":"PA Sarafidis","year":"2012","unstructured":"Sarafidis\u00a0PA, Ruilope\u00a0LM (2012) Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression. J\u00a0Renin Angiotensin Aldosterone Syst 13(1):217\u2013219","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"20","key":"1297_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis\u00a0EJ, Hunsicker\u00a0LG, Bain\u00a0RP, Rohde\u00a0RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N\u00a0Engl J Med 329(20):1456\u20131462","journal-title":"N Engl J Med"},{"issue":"12","key":"1297_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner\u00a0BM, Cooper\u00a0ME, de Zeeuw\u00a0D, Keane\u00a0WF, Mitch\u00a0WE, Parving\u00a0HH, Remuzzi\u00a0G, Snapinn\u00a0SM, Zhang\u00a0Z, Shahinfar\u00a0S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N\u00a0Engl J Med 345(12):861\u2013869","journal-title":"N Engl J Med"},{"issue":"12","key":"1297_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis\u00a0EJ, Hunsicker\u00a0LG, Clarke\u00a0WR, Berl\u00a0T, Pohl\u00a0MA, Lewis\u00a0JB, Ritz\u00a0E, Atkins\u00a0RC, Rohde\u00a0R, Raz\u00a0I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N\u00a0Engl J Med 345(12):851\u2013860","journal-title":"N Engl J Med"},{"issue":"23","key":"1297_CR9","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving\u00a0HH, Brenner\u00a0BM, McMurray\u00a0JJ, de Zeeuw\u00a0D, Haffner\u00a0SM, Solomon\u00a0SD, Chaturvedi\u00a0N, Persson\u00a0F, Desai\u00a0AS, Nicolaides\u00a0M, Richard\u00a0A, Xiang\u00a0Z, Brunel\u00a0P, Pfeffer\u00a0MA, ALTITUDE Investigators (2012) Cardiorenal end points in a\u00a0trial of aliskiren for type 2 diabetes. N\u00a0Engl J Med 367(23):2204\u20132213","journal-title":"N Engl J Med"},{"issue":"20","key":"1297_CR10","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried\u00a0LF, Emanuele\u00a0N, Zhang\u00a0JH, Brophy\u00a0M, Conner\u00a0TA, Duckworth\u00a0W, Leehey\u00a0DJ, McCullough\u00a0PA, O\u2019Connor\u00a0T, Palevsky\u00a0PM, Reilly\u00a0RF, Seliger\u00a0SL, Warren\u00a0SR, Watnick\u00a0S, Peduzzi\u00a0P, Guarino\u00a0P, VA NEPHRON\u2011D Investigators (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N\u00a0Engl J Med 369(20):1892\u20131903","journal-title":"N Engl J Med"},{"issue":"2","key":"1297_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback\u00a0AS, Kshirsagar\u00a0AV, Amamoo\u00a0MA, Klemmer\u00a0PJ (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a\u00a0systematic review. Am J Kidney Dis 51(2):199\u2013211","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"1297_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD, Pitt\u00a0B, Ruilope\u00a0LM, Rossing\u00a0P, Kolkhof\u00a0P, Nowack\u00a0C, Schloemer\u00a0P, Joseph\u00a0A, Filippatos\u00a0G, FIDELIO-DKD Investigators (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N\u00a0Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"10254","key":"1297_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad\u00a0F, Ferreira\u00a0JP, Pocock\u00a0SJ, Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G, Brueckmann\u00a0M, Ofstad\u00a0AP, Pfarr\u00a0E, Jamal\u00a0W, Packer\u00a0M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a\u00a0meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819\u2013829","journal-title":"Lancet"},{"issue":"21","key":"1297_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE, K\u00f8ber\u00a0L, Kosiborod\u00a0MN, Martinez\u00a0FA, Ponikowski\u00a0P, Sabatine\u00a0MS, Anand\u00a0IS, B\u011blohl\u00e1vek\u00a0J, B\u00f6hm\u00a0M, Chiang\u00a0CE, Chopra\u00a0VK, de Boer\u00a0RA, Desai\u00a0AS, Diez\u00a0M, Drozdz\u00a0J, Duk\u00e1t\u00a0A, Ge\u00a0J, Howlett\u00a0JG, Katova\u00a0T, Kitakaze\u00a0M, Ljungman\u00a0CEA, Merkely\u00a0B, Nicolau\u00a0JC, O\u2019Meara\u00a0E, Petrie\u00a0MC, Vinh\u00a0PN, Schou\u00a0M, Tereshchenko\u00a0S, Verma\u00a0S, Held\u00a0C, DeMets\u00a0DL, Docherty\u00a0KF, Jhund\u00a0PS, Bengtsson\u00a0O, Sj\u00f6strand\u00a0M, Langkilde\u00a0AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"4","key":"1297_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","volume":"143","author":"PS Jhund","year":"2021","unstructured":"Jhund\u00a0PS, Solomon\u00a0SD, Docherty\u00a0KF, Heerspink\u00a0HJL, Anand\u00a0IS, B\u00f6hm\u00a0M, Chopra\u00a0V, de Boer\u00a0RA, Desai\u00a0AS, Ge\u00a0J, Kitakaze\u00a0M, Merkley\u00a0B, O\u2019Meara\u00a0E, Shou\u00a0M, Tereshchenko\u00a0S, Verma\u00a0S, Vinh\u00a0PN, Inzucchi\u00a0SE, K\u00f8ber\u00a0L, Kosiborod\u00a0MN, Martinez\u00a0FA, Ponikowski\u00a0P, Sabatine\u00a0MS, Bengtsson\u00a0O, Langkilde\u00a0AM, Sj\u00f6strand\u00a0M, McMurray\u00a0JJV (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143(4):298\u2013309","journal-title":"Circulation"},{"issue":"15","key":"1297_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G, Pocock\u00a0SJ, Carson\u00a0P, Januzzi\u00a0J, Verma\u00a0S, Tsutsui\u00a0H, Brueckmann\u00a0M, Jamal\u00a0W, Kimura\u00a0K, Schnee\u00a0J, Zeller\u00a0C, Cotton\u00a0D, Bocchi\u00a0E, B\u00f6hm\u00a0M, Choi\u00a0DJ, Chopra\u00a0V, Chuquiure\u00a0E, Giannetti\u00a0N, Janssens\u00a0S, Zhang\u00a0J, Gonzalez Juanatey\u00a0JR, Kaul\u00a0S, Brunner-La Rocca\u00a0HP, Merkely\u00a0B, Nicholls\u00a0SJ, Perrone\u00a0S, Pina\u00a0I, Ponikowski\u00a0P, Sattar\u00a0N, Senni\u00a0M, Seronde\u00a0MF, Spinar\u00a0J, Squire\u00a0I, Taddei\u00a0S, Wanner\u00a0C, Zannad\u00a0F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"7","key":"1297_CR17","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffey\u00a0KW, de Zeeuw\u00a0D, Fulcher\u00a0G, Erondu\u00a0N, Shaw\u00a0W, Law\u00a0G, Desai\u00a0M, Matthews\u00a0DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"15","key":"1297_CR18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon\u00a0CP, Pratley\u00a0R, Dagogo-Jack\u00a0S, Mancuso\u00a0J, Huyck\u00a0S, Masiukiewicz\u00a0U, Charbonnel\u00a0B, Frederich\u00a0R, Gallo\u00a0S, Cosentino\u00a0F, Shih\u00a0WJ, Gantz\u00a0I, Terra\u00a0SG, Cherney\u00a0DZI, McGuire\u00a0DK, VERTIS CV Investigators (2020) Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N\u00a0Engl J Med 383(15):1425\u20131435","journal-title":"N Engl J Med"},{"issue":"2","key":"1297_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt\u00a0DL, Szarek\u00a0M, Pitt\u00a0B, Cannon\u00a0CP, Leiter\u00a0LA, McGuire\u00a0DK, Lewis\u00a0JB, Riddle\u00a0MC, Inzucchi\u00a0SE, Kosiborod\u00a0MN, Cherney\u00a0DZI, Dwyer\u00a0JP, Scirica\u00a0BM, Bailey\u00a0CJ, D\u00edaz\u00a0R, Ray\u00a0KK, Udell\u00a0JA, Lopes\u00a0RD, Lapuerta\u00a0P, Steg\u00a0PG, SCORED Investigators (2021) Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N\u00a0Engl J Med 384(2):129\u2013139","journal-title":"N Engl J Med"},{"issue":"4","key":"1297_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker\u00a0TA, Braunwald\u00a0E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-Art review. J\u00a0Am Coll Cardiol 75(4):422\u2013434","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1297_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","volume":"73","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma\u00a0T, Jun\u00a0M, Rodgers\u00a0A, Cooper\u00a0ME, Glasziou\u00a0P, Hamet\u00a0P, Harrap\u00a0S, Mancia\u00a0G, Marre\u00a0M, Neal\u00a0B, Perkovic\u00a0V, Poulter\u00a0N, Williams\u00a0B, Zoungas\u00a0S, Chalmers\u00a0J, Woodward\u00a0M, ADVANCE Collaborative Group (2019) Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus. Hypertension 73(1):84\u201391","journal-title":"Hypertension"},{"issue":"1","key":"1297_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","volume":"16","author":"M Zhao","year":"2020","unstructured":"Zhao\u00a0M, Sun\u00a0S, Huang\u00a0Z, Wang\u00a0T, Tang\u00a0H (2020) Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol 16(1):70\u201378","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"1297_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, Jardine\u00a0MJ, Neal\u00a0B, Bompoint\u00a0S, Heerspink\u00a0HJL, Charytan\u00a0DM, Edwards\u00a0R, Agarwal\u00a0R, Bakris\u00a0G, Bull\u00a0S, Cannon\u00a0CP, Capuano\u00a0G, Chu\u00a0PL, de Zeeuw\u00a0D, Greene\u00a0T, Levin\u00a0A, Pollock\u00a0C, Wheeler\u00a0DC, Yavin\u00a0Y, Zhang\u00a0H, Zinman\u00a0B, Meininger\u00a0G, Brenner\u00a0BM, Mahaffey\u00a0KW, CREDENCE Trial Investigators (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N\u00a0Engl J Med 380(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"15","key":"1297_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0FF, Mann\u00a0JFE, McMurray\u00a0JJV, Lindberg\u00a0M, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Toto\u00a0RD, Langkilde\u00a0AM, Wheeler\u00a0DC, DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"1","key":"1297_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Stef\u00e1nsson\u00a0BV, Jongs\u00a0N, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0FF, McMurray\u00a0JJV, Correa-Rotter\u00a0R, Rossing\u00a0P, Toto\u00a0RD, Sj\u00f6str\u00f6m\u00a0CD, Langkilde\u00a0AM, Heerspink\u00a0HJL, DAPA-CKD Trial Committees and Investigators (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a\u00a0prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(1):22\u201331","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1297_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Toto\u00a0RD, Stef\u00e1nsson\u00a0BV, Jongs\u00a0N, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0FF, McMurray\u00a0JJV, Pecoits-Filho\u00a0R, Correa-Rotter\u00a0R, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Umanath\u00a0K, Langkilde\u00a0AM, Heerspink\u00a0HJL, DAPA-CKD Trial Committees and Investigators (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215\u2013224","journal-title":"Kidney Int"},{"issue":"4","key":"1297_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen\u00a0T, Wied\u00a0S, Fitzner\u00a0C, Eitner\u00a0F, Sommerer\u00a0C, Zeier\u00a0M, Otte\u00a0B, Panzer\u00a0U, Budde\u00a0K, Benck\u00a0U, Mertens\u00a0PR, Kuhlmann\u00a0U, Witzke\u00a0O, Gross\u00a0O, Vielhauer\u00a0V, Mann\u00a0JFE, Hilgers\u00a0RD, Floege\u00a0J, STOP-IgAN Investigators (2020) After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98(4):1044\u20131052","journal-title":"Kidney Int"},{"issue":"9","key":"1297_CR28","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow\u00a0GM, Vart\u00a0P, Jongs\u00a0N, Toto\u00a0RD, Gorriz\u00a0JL, Hou\u00a0FF, McMurray\u00a0JJV, Correa-Rotter\u00a0R, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Stef\u00e1nsson\u00a0BV, Langkilde\u00a0AM, Wheeler\u00a0DC, Heerspink\u00a0HJL, DAPA-CKD Trial Committees and Investigators (2021) Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J\u00a0Am Soc Nephrol 32(9):2352\u20132361","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1297_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock\u00a0J, Perkovic\u00a0V, Johansen\u00a0OE, Cooper\u00a0ME, Kahn\u00a0SE, Marx\u00a0N, Alexander\u00a0JH, Pencina\u00a0M, Toto\u00a0RD, Wanner\u00a0C, Zinman\u00a0B, Woerle\u00a0HJ, Baanstra\u00a0D, Pfarr\u00a0E, Schnaidt\u00a0S, Meinicke\u00a0T, George\u00a0JT, von Eynatten\u00a0M, McGuire\u00a0DK, CARMELINA Investigators (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(1):69\u201379","journal-title":"JAMA"},{"issue":"17","key":"1297_CR30","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker\u00a0TA, Wiviott\u00a0SD, Raz\u00a0I, Im\u00a0K, Goodrich\u00a0EL, Furtado\u00a0RHM, Bonaca\u00a0MP, Mosenzon\u00a0O, Kato\u00a0ET, Cahn\u00a0A, Bhatt\u00a0DL, Leiter\u00a0LA, McGuire\u00a0DK, Wilding\u00a0JPH, Sabatine\u00a0MS (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139(17):2022\u20132031","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s00108-022-01468-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000}},{"DOI":"10.1007\/s00108-022-01417-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000}}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01297-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:46:24Z","timestamp":1674578784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01297-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01297-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"9 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-022-01468-9","URL":"https:\/\/doi.org\/10.1007\/s00108-022-01468-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-022-01417-6","URL":"https:\/\/doi.org\/10.1007\/s00108-022-01417-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Beimler gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}